News >

Expert Highlights Advances in CAR T-Cell Therapy

Angelica Welch
Published: Tuesday, Dec 05, 2017

Noelle Frey, MD

Noelle Frey, MD
As tisagenlecleucel (Kymriah) makes its way through the hematologic landscape and the October 2017 FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta) brings hope to larger populations with patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor (CAR) T-cell therapy arena continues its meteoric rise.

on Hematologic Malignancies, Frey, assistant professor of medicine at the Perelman School of Medicine at the University of Pennsylvania, discussed the FDA approvals of CAR T-cell therapies, as well as the bright future of the treatment.

OncLive: Can you provide an overview of your lecture on CAR T-cell therapy?

Frey: I spoke about CAR T-cell therapy and how that is helpful for patients who have certain malignancies, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas. I have to say, it is an exciting time to be giving this talk because…there are now 2 FDA-approved CAR T-cell therapies that will be very helpful for our patients going forward.

Can you expand on the CAR T-cell therapies that are now available?

The first therapy, tisagenlecleucel, was approved in August 2017, and this is a CAR T-cell product directed to CD19 that is FDA approved for pediatric and young adult patients up to the age of 25. It was approved in the setting of a large multicenter, multinational study that showed a significant benefit for this patient population with relapsed and refractory disease, who otherwise have very limited treatment options. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x